期刊文献+

罗替戈汀透皮贴剂的体外透皮特性 被引量:6

The transdermal behavior of rotigotine transdermal patch in vitro
原文传递
导出
摘要 目的:研究罗替戈汀透皮贴剂对离体豚鼠皮的透皮吸收情况,比较自制贴剂与国外已上市产品的离体透皮过程。方法:采用改进Franz扩散池,于实验开始后不同时间点取样,用HPLC法测定样品中罗替戈汀的浓度。结果:自制贴剂和国外贴剂的体外透皮稳态速率分别为9.210,8.796μg.cm-2.h-1,二者透皮速率无显著性差异。实验结束揭去贴片后,贴片及皮肤中均有少量的药物残留,约为药物总量的2%~4%。结论:自制罗替戈汀贴剂有良好的透皮性能,其豚鼠离体透皮吸收程度与国外同类品种相当。 OBJECTIVE To investigate the percutaneous absorption of rotigotine transdermal patch through guinea pig skins,and compare in vitro the penetration release of self-made patches with foreign products already in marlcet.METHODS Using a modified Franz diffusion cell,samples were collected at various time points after the start of test.The concentrations of rotigotine in the samples were measured by HPLC.RESULTS The steady penetration rates of rotigotine of self-made products and foreign products in vitro were 9.210 μg·cm-2·h-1,8.796 μg·cm-2·h-1,respectively.There was no significant difference among the permeation rates of two products.Rotigotine residues were detected in the patches and skins after the two sources of the patches were removed from the tested skins.The amount of rotigotine residues counted for 2%~4% of the total medicine in patches.CONCLUSION The self-made patches have good property of penetration,and the percutaneous absorption through guinea pig skins are similar to foreign products.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2013年第10期779-782,共4页 Chinese Journal of Hospital Pharmacy
关键词 罗替戈汀 透皮贴剂 经皮渗透 rotigotine transdermal patch percutaneous permeation
  • 相关文献

参考文献12

  • 1Samii A, Nutt JG, Ransom BR. Parkinson' s disease [J].Lancet, 2004, 363 (9423): 1783-1793.
  • 2Zareba G. Rotigotine: a novel dopamine agonist for the trans- dermal treatment of Parkinson disease[J].Drugs Today (Barc), 2006, 42(1): 21-8.
  • 3Braun M, Elshoff JP, Andreas JO, el al. Influence of trans- dermal rotigotine on ovulation suppression by a combined oral contraceptive[J]. Br J Clin Pharmaco, 2009, 68(3) : 386 -394.
  • 4郭威,王少云,傅得兴,聂颖兰.罗替戈汀透皮贴剂的药理及临床研究进展[J].中国新药杂志,2008,17(8):705-708. 被引量:4
  • 5Jenner P. A novel dopamine agonist for the transdermat treat- ment of Parkinson' s disease [J]. Neurology, 2005, 65 (2Suppl. 1):S3-5.
  • 6Reynolds NA, Wellington K, Easthope SE. Rotigotine in Parkinson's disease[J]. CNS Drugs, 2006, 19 (11 ) : 973 - 981.
  • 7The Parkinson study group. A controlled trial of rotigotine monotherapy in early Parkinsons disease[J], Arch Neurol,2003, 60(12):1721-1728.
  • 8Krishna PM, Rao BT, Kumar RK, et al. A Stability indica- ting of Rotigotine in Bulk Drugs by HPLC Assay method[J]. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 2010, 1(4): 848-857.
  • 9Waiters DL,Strong CR, Green SV, at at. Development and validation of a gradient reversed-phase high-performance liquid chromatographic assay for S(-) 2-(N-propyl-N 2 thienylethyl- amino)-5-hydroxytetralin (N-0923)from a transdermal deliver- y syatem[J]. Chromatogr B Biomed Appl, 1995, 670(2) : 299-307.
  • 10吕文莉,郭健新,平其能.灯盏花素脂质体的制备及其理化性质的测定[J].中国天然药物,2004,2(5):289-292. 被引量:28

二级参考文献25

  • 1BOQUCKI A, GAJOS A. Choosing a dopamine agonist in Parkinson's disease [ J ]. Neurol Neurochir Pol,2007,41 ( 2 Suppl 1): S14-S21.
  • 2BARA-JIMENEZ W, BIBBIANI F, MORRIS MJ, et al. Effects of serotonin 5-HTI A agonist in advanced Parkinson's disease[ J ]. Mov Disord, 2005,20( 8 ) :932 - 936.
  • 3ROSE S,SCHELLER DK, BREIDENBACH A, et al. Plasma levels of rotigotine and the reversal of motor deficits in MPTP- treated primates [ J ]. Behav Pharmacol, 2007,18 ( 2 ) : 155 - 160.
  • 4SCHELLER D, CHAN P, LI Q, et al. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease [ J ]. Exp Neurol, 2007,203 ( 2 ) : 415 - 422.
  • 5KEHR J, HU XJ, GOINY M, et al. Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation[J]. J Neural Transm, 2007,114(8) :1027 - 1031.
  • 6HUTTON JT, METMAN LV, CHASE TN, et al. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study [J]. Mov Disord, 2001,16(3): 459 -463.
  • 7NYHOLM D. Pharmacokinetic optimisation in the treatment of Parkinson' disease : an update [ J ]. Clin Pharmacokinet, 2006, 45(2) :109 - 136.
  • 8THE PARKINSON STUDY GROUP. A controlled trial of rotigotine monotherapy in early Parkinson's disease [ J]. Arch Neurol, 2003,60(12) :1721 - 1728.
  • 9BELDEN H. Patch offers new option for early Parkinson's[ J]. Drug Top, 2007,14(6) :11 - 12.
  • 10MUCKE HA. Rotigotine Schwarz Pharma[ J]. IDrugs, 2003,6 (9) :894 - 899.

共引文献30

同被引文献59

  • 1刘玉莲,杨丛忠.黄芪药理作用概述[J].中国药业,2004,13(10):79-79. 被引量:87
  • 2陈爱芳,崔志清.黄杨宁的临床和实验研究近况[J].中华中医药学刊,2007,25(4):767-769. 被引量:10
  • 3中国药典一部[S].2010年:32.
  • 4Karadzovska D, Riviere JE. Assessing vehicle effects on skin absorption using artificial membrane assays[J]. Eur J Pharm Sci,2013,50(5) :569-576.
  • 5Samii A, Nutt JG, Ransom BR. Parkinson's disease [J]. Lancet, 2004, 363 (9423) : 1783-1793.
  • 6Zareba G. Rotigotine: a novel dopamine agonist for the trans- dermal treatment of Parkinson's disease [J]. Drugs Today (Barc), 2006, 42 (1) : 21-28.
  • 7Braun M, Elshoff JP, Andreas JO, et al. Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive [J]. Br J Clin Pharmacol, 2009, 68 (3) : 386-394.
  • 8Zhao L, Fang L, Xu Y, et al. Transdermal delivery of penetrants with differing lipophilicities using O-acylmenthol derivatives as penetration enhancers [ J]. Eur J Pharm Biopharm, 2008, 69 (1) : 199-213.
  • 9Zhao L, Fang L, Xu Y, et al. Effect of O-acylmenthol on transdermal delivery of drugs with different lipophilicity [J]. Int JPharm, 2008, 352 (1-2) : 92-103.
  • 10Karadzovska D,Riviere JE.Assessing vehicle effects on skin absorption using artificial membrane assays[J].Eur J Pharm Sci,2013,50(5):569-576.

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部